Regrow's cell therapy product gets orphan drug status from USFDA

Start-up in talks with MNCsto out-license Ossgrow for developed markets

Mumbai-based biotech start-up Regrow Biosciences that developed cell-therapy based solution for orthopaedic joint issues is in talks with multinational firms to out-license its product for commercialisation in the US and other developed markets. It has recently received orphan drug designation (ODD) from the US drug regulator and expects the same from its European counterpart this month. 

The development would further fuel Regrow’s ambitions to fetch higher value for its innovation which it claims is the only approved product (using the stem cell therapy) to treat early-stage avascular necrosis of bone joints. Necrosis is basically death of bone tissue due to interruptions